PLATINUM RESISTANCE IS ONE OF THE MOST CHALLENGING ASPECTS OF OVARIAN CANCER TREATMENT

Definitions of Platinum Sensitivity Are Based on Platinum-Free Interval

<table>
<thead>
<tr>
<th>Time from last platinum exposure to progressive disease:</th>
<th>≥6 months</th>
<th>1–6 months</th>
<th>&lt;1 month</th>
</tr>
</thead>
<tbody>
<tr>
<td>Platinum-sensitive</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Platinum-refractory</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Platinum-resistant</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Platinum Resistance Is Associated With Poor Prognosis

- Platinum-resistant disease
  - mOS: 9–12 months

- Platinum-refractory disease
  - mOS: 3–5 months

Treatment Options for Platinum-Resistant Ovarian Cancer (PROC) Are Associated With Clinical Response and May Provide Symptom Palliation

- Single-agent chemotherapy
  - Double-agent chemotherapy is not generally used; it provides similar responses but has more toxicity than single-agent therapy

- Chemotherapy plus bevacizumab
  - Addition of bevacizumab to chemotherapy improves response, PFS, and QoL, but does not prolong OS

- PARP inhibitors
  - Currently, some PARP inhibitors are approved for treatment of BRCA<sup>mut</sup> PROC

Clinical trials

- Enrollment in a clinical trial remains the best opportunity for many patients

Treatment Goals for Patients With PROC

- Disease control
- Prolongation of life
- Palliation of symptoms
- QoL improvement

New Agents and Combinations Are Being Developed for Treatment of PROC

- Other angiogenesis inhibitors
- Folate receptor inhibitors
- Immunotherapeutic strategies
- Drug candidates targeting mutant p53
- Targeted therapies against signaling pathways

PROC is associated with poor survival outcomes

Treatment options include chemotherapy ± anti-angiogenics or PARPi monotherapy

Many new therapies and combinations are under investigation

Clinical trials should be strongly considered for patients with PROC

For additional content on this topic, please visit www.GemstoneOncology.com

References:
- Rucaparib package insert. Clovis Oncology, Inc; April 2018.

* Median OS values shown for recurrence after 1L chemotherapy; platinum-refractory/resistant definitions often applied after multiple lines of therapy.

1L, first line; BRCA, breast cancer susceptibility gene; mOS, median OS; mut, mutation; OS, overall survival; PARP, poly ADP ribose polymerase; PARPi, PARP inhibitor; PFS, progression-free survival; PROC, platinum-resistant ovarian cancer; QoL, quality of life.